Cost-effectiveness of Ontario's pandemic vaccine program.
Rolland-Harris
Elizabeth
E
Tepper
Martin
M
D003362:Cost-Benefit Analysis; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000191:economics* / Q000276:immunology; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D015233:Models, Statistical; D009864:Ontario / Q000453:epidemiology; D058873:Pandemics / Q000517:prevention & control*
D007252:Influenza Vaccines